Navigation Links
Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Date:6/4/2008

SEATTLE, June 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Dr. Kendall Mohler, co-founder and senior vice president of research and development, is scheduled to present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference on June 12 at 10 a.m. EDT. This conference will be held at the New York Palace Hotel in New York City. The presentation will be available via audio webcast at http://www.wsw.com/webcast/needham25/trbn/ and will be available in the investors section of Trubion's website, investors.trubion.com.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Contact:

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788

amyp@waggeneredstrom.com

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Announces Presentations at April/May Investor Conferences
2. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
3. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
4. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
7. Onyx Pharmaceuticals to Present at Goldman Sachs 29th Annual Global Healthcare Conference
8. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
9. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
10. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
11. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... December 8, 2016 Oxford Gene ... customisable SureSeq™ NGS panel range with the launch of the ... cost-effective study of variants in familial hypercholesterolemia (FH). The panel ... detection on a single small panel and allows customisation by ... includes all exons for LDLR , P ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial ... Technology Awards. uBiome is one of just six company finalists in the Health ... addition to uBiome, companies nominated as finalists in this year’s awards include Google, ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... ), a leading commercial provider of clinically actionable ... cancer patients, announces that clinical data featuring its ... concordance to tissue biopsy for the detection of ... The results from research sponsored by Sara Cannon ...
Breaking Biology Technology:
(Date:12/2/2016)... PUNE, India , December 1, 2016 /PRNewswire/ ... Market by Authentication type (Fingerprint, Voice), Future Technology (Iris ... Vehicle), and Region - Global Forecast to 2021", ... be USD 442.7 Million in 2016, and is ... 2021, at a CAGR of 14.06%. ...
(Date:11/30/2016)... -- higi SH llc (higi) announced today the launch ... industry thought-leaders and celebrity influencers looking to encourage, ... steps to live healthier, more active lives. ... built the largest self-screening health station network in ... have conducted over 185 million biometric screenings.  The ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
Breaking Biology News(10 mins):